Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality

药房纳洛酮分布:评估降低用药过量死亡率的新工具

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Drug overdose is the leading cause of injury death among adults aged 25 to 64 years in the United States. The number of fatal overdoses involving opioid pain relievers nearly quadrupled between 1999 and 2013, and fatal overdoses related to heroin almost tripled between 2010 and 2013. Public health interventions designed to reduce opioid overdose deaths are urgently needed. Naloxone is an opioid antagonist that "reverses" opioid overdoses. Increased access to naloxone has been shown to reduce opioid overdose mortality; however, naloxone is a prescription drug, which limits opportunities to expand its distribution. In March 2014, Massachusetts established an innovative program that allows the issuance of naloxone standing orders (NSO) at community pharmacies. Under NSO, pharmacies can dispense naloxone to any individual at risk of having, or witnessing, an opioid overdose. Massachusetts is one of the first states to implement a pharmacy-based naloxone distribution program on a broad scale, but a growing number of states are passing legislation to authorize these programs. Accordingly, Massachusetts represents an important and timely "natural experiment" in expanding naloxone access through community pharmacies. This study will use a multiphase mixed methods research design to assess the implementation and impact of the Massachusetts NSO program. Specifically, this study will (1) characterize implementation of the Massachusetts NSO program and assess barriers and facilitators to pharmacy participation and proper dispensing; (2) examine the acceptability of pharmacy-based naloxone dispensing to illicit opioid users and potential overdose bystanders and identify factors that would increase acceptance for these two groups; and (3) assess the impact of the pharmacy NSO program on overdose mortality. At the conclusion of our study, we will have generated a comprehensive understanding of the factors that influence the implementation and impact of one of the first statewide pharmacy-based naloxone dispensing programs in the United States. Our findings will be of considerable value to the growing number of states considering and/or implementing NSO programs as part of their overall strategy to reduce the public health burden of opioid overdose mortality.
 描述(由申请人提供):药物过量是美国 25 至 64 岁成年人受伤死亡的主要原因。 1999 年至 2013 年间,涉及阿片类止痛药的致命过量用药数量几乎增加了四倍,而 2010 年至 2013 年间,与海洛因相关的致命过量用药几乎增加了两倍。迫切需要旨在减少阿片类药物过量死亡的公共卫生干预措施。纳洛酮是一种阿片类拮抗剂,可“逆转”阿片类药物过量。增加纳洛酮的获取已被证明可以降低阿片类药物过量死亡率;然而,纳洛酮是一种处方药,这限制了扩大其分销的机会。 2014 年 3 月,马萨诸塞州制定了一项创新计划,允许在社区药房发放纳洛酮常规订单 (NSO)。根据 NSO,药房可以向任何有或目睹阿片类药物过量风险的个人分发纳洛酮。马萨诸塞州是首批大规模实施基于药房的纳洛酮分配计划的州之一,但越来越多的州正在通过立法来授权这些计划。因此,马萨诸塞州代表着一项重要而及时的“自然实验”,旨在通过社区药房扩大纳洛酮的获取。本研究将采用多阶段混合方法研究设计来评估马萨诸塞州国家统计局计划的实施和影响。具体来说,本研究将 (1) 描述马萨诸塞州 NSO 计划的实施情况,并评估药房参与和正确配药的障碍和促进因素; (2) 检查非法阿片类药物使用者和潜在过量用药旁观者对基于药房的纳洛酮配药的可接受性,并确定可提高这两类人群接受度的因素; (3) 评估药房 NSO 计划对用药过量死亡率的影响。在我们的研究结束时,我们将对影响美国第一个全州药房纳洛酮配药计划的实施和影响的因素有一个全面的了解。我们的研究结果对于越来越多考虑和/或实施 NSO 计划作为其总体战略的一部分的国家具有相当大的价值,以减少阿片类药物过量死亡率的公共卫生负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robin A Pollini其他文献

Robin A Pollini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robin A Pollini', 18)}}的其他基金

Identifying Stigma Reduction Targets in the Context of an Appalachian HIV Outbreak
在阿巴拉契亚艾滋病毒爆发的背景下确定减少耻辱的目标
  • 批准号:
    10415554
  • 财政年份:
    2022
  • 资助金额:
    $ 66.17万
  • 项目类别:
Identifying Stigma Reduction Targets in the Context of an Appalachian HIV Outbreak
在阿巴拉契亚艾滋病毒爆发的背景下确定减少耻辱的目标
  • 批准号:
    10670313
  • 财政年份:
    2022
  • 资助金额:
    $ 66.17万
  • 项目类别:
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality
药房纳洛酮分布:评估降低用药过量死亡率的新工具
  • 批准号:
    9629678
  • 财政年份:
    2017
  • 资助金额:
    $ 66.17万
  • 项目类别:
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality
药房纳洛酮分布:评估降低用药过量死亡率的新工具
  • 批准号:
    10092988
  • 财政年份:
    2017
  • 资助金额:
    $ 66.17万
  • 项目类别:
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California
销售非处方药注射器以预防加利福尼亚州内陆服务欠缺地区的艾滋病毒
  • 批准号:
    8466903
  • 财政年份:
    2013
  • 资助金额:
    $ 66.17万
  • 项目类别:
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California
销售非处方药注射器以预防加利福尼亚州内陆服务欠缺地区的艾滋病毒
  • 批准号:
    8780622
  • 财政年份:
    2013
  • 资助金额:
    $ 66.17万
  • 项目类别:
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California
销售非处方药注射器以预防加利福尼亚州内陆服务欠缺地区的艾滋病毒
  • 批准号:
    8601068
  • 财政年份:
    2013
  • 资助金额:
    $ 66.17万
  • 项目类别:
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach
定义墨西哥药房在艾滋病毒预防中的作用——混合方法
  • 批准号:
    8283008
  • 财政年份:
    2007
  • 资助金额:
    $ 66.17万
  • 项目类别:
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach
定义墨西哥药房在艾滋病毒预防中的作用——混合方法
  • 批准号:
    7497029
  • 财政年份:
    2007
  • 资助金额:
    $ 66.17万
  • 项目类别:
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach
定义墨西哥药房在艾滋病毒预防中的作用——混合方法
  • 批准号:
    7908794
  • 财政年份:
    2007
  • 资助金额:
    $ 66.17万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 66.17万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了